Celcuity Inc. (CELC)
CELC$4.72B
Mid CapNASDAQServices-Medical Laboratories🇺🇸North AmericaMINNEAPOLIS
Drugs in Pipeline
3
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Jun 30, 2026
13wMarket Overview
Stock performance and key metrics
CELC News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant
Breast Cancer
Gedatolisib
mCRPC (Metastatic Castration-resistant Prostate Cancer)
Palbociclib
Breast Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Arm A: Gedatolisib + Palbociclib or Ribociclib + Fulvestrant | Phase 3 | Breast Cancer | - | - |
Gedatolisib | Phase 3 | mCRPC (Metastatic Castration-resistant Prostate Cancer) | - | - |
Palbociclib | Phase 3 | Breast Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply